Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% - Should You Sell?

Key Points

• Telomir Pharmaceuticals shares fell 3.4% to $1.13 in midday trading, with volume down 74% from the average. The company has a market capitalization of approximately $77.7 million and trades below its 50- and 200-day moving averages.
• Analyst sentiment is mixed: one analyst rates the stock Buy, one Hold and one Sell, while Weiss Ratings recently reaffirmed a “sell (e+)” rating. MarketBeat’s average rating is “Hold.”
• The clinical-stage biopharmaceutical company reported quarterly EPS of negative $0.03, beating the consensus estimate of negative $0.07. Several institutions recently initiated or increased positions, including BlackRock, Geode Capital Management and Raymond James.

Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) were down 3.4% during mid-day trading on Tuesday . The company traded as low as $1.13 and last traded at $1.13. 27,578 shares traded hands during trading, a decline of 74% from the average daily volume of 104,128 shares. The stock had previously closed at $1.17.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Telomir Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Telomir Pharmaceuticals presently has an average rating of "Hold".

Telomir Pharmaceuticals Stock Performance

The firm has a market capitalization of $77.72 million, a P/E ratio of -3.90 and a beta of -0.24. The firm has a 50 day simple moving average of $1.22 and a two-hundred day simple moving average of $1.26.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.04.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Telomir Pharmaceuticals during the 2nd quarter worth approximately $359,000. Geode Capital Management LLC grew its holdings in shares of Telomir Pharmaceuticals by 14.0% in the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company's stock valued at $297,000 after acquiring an additional 27,519 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $95,000. Raymond James Financial Inc. increased its position in shares of Telomir Pharmaceuticals by 4,101.9% during the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company's stock valued at $105,000 after acquiring an additional 73,547 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Telomir Pharmaceuticals during the second quarter valued at approximately $66,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc NASDAQ: TELO is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company's lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source